Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607598 | 0.81 | HDAC6 (0.53) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL1608325 | 0.80 | HDAC6 (0.46) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL1608210 | 0.80 | HDAC6 (0.57) | HDAC6HDAC1HDAC2HDAC3PPARG | |
| SCHEMBL1608623 | 0.80 | JAK1 (0.44) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL1608324 | 0.79 | HDAC6 (0.42) | HDAC6HDAC1HDAC2HDAC3LMNA | |
| SCHEMBL1607548 | 0.78 | HDAC1 (0.46) | HDAC6HDAC1HDAC2HDAC3PPARG | |
| SCHEMBL3431726 | 0.78 | HDAC6 (0.57) | HDAC6HDAC1HDAC2HDAC3HDAC8 | |
| SCHEMBL1607822 | 0.77 | HDAC2 (0.47) | HDAC6HDAC1HDAC2HDAC3PPARG | |
| SCHEMBL1609002 | 0.77 | FLT1 (0.46) | HDAC6HDAC1HDAC2HDAC3PPARG | |
| SCHEMBL1608086 | 0.77 | HDAC6 (0.46) | HDAC6HDAC1HDAC2HDAC3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320758-A1 | SELECTIVE INHIBITORS OF HISTONE DEACTYLASE | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| US-8906954-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140004174-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8466193-B2 | Selective inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110081409-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS LLC | 2011-04-07 | — | — | US | disclosed |
| EP-2265590-A2 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009129335-A2 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081409-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC11 | HDAC6 11/4885HDAC1 2/4885HDAC2 7/4885 |
| US-20150320758-A1 | SELECTIVE INHIBITORS OF HISTONE DEACTYLASE | HDAC8, HDAC1, HDAC5 | HDAC6 11/4885HDAC1 2/4885HDAC2 4/4885 |
| US-20140004174-A1 | SELECTIVE INHIBITORS OF HISTONE DEACETYLASE | HDAC8, HDAC1, HDAC11 | HDAC6 11/4885HDAC1 2/4885HDAC2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.